Subcellular localization of hTERT in breast cancer: insights into its tumorigenesis and drug resistance mechanisms in HER2-immunopositive breast cancer-Reference-Cited by-同舟云学术

Subcellular localization of hTERT in breast cancer: insights into its tumorigenesis and drug resistance mechanisms in HER2-immunopositive breast cancer

Published:2023-04 Issue: Volume:134 Page:74-84
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

Uno Yuji,Tanaka Hiroki,Miyakawa Keita,Akiyama Naoko,Kamikokura Yuki,Yuzawa Sayaka,Kitada Masahiro,Takei Hidehiro,Tanino Mishie^ORCID

Funder

Asahikawa Medical University

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference32 articles.

1. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer;Prat;Breast Cancer Res,2010

2. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer;Nami;Cancers (Basel),2018

3. Resistance to trastuzumab in breast cancer;Pohlmann;Clin Cancer Res,2009

4. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis;Hannen;FEBS Lett,2018

5. Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer;Leao;J Biomed Sci,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation and clinical potential of telomerase reverse transcriptase (TERT/hTERT) in breast cancer;Cell Communication and Signaling;2023-08-23

2. Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer;Current Oncology;2023-04-07